A Saiz / F Graus (HCP)

The group is focused in the study of biomarkers and clinical markers involved in the diagnosis, prognosis and therapeutics of MS. Our laboratory is an European reference center for the study of antineuronal antibodies including NMO-IgG/AQP-4 antibodies. Our group has one of the larger experience in MS patients treated with autologous hematopoietic stem cell transplantation, and is currently conducting a phase II trial on autologous mesenchymal stem cell transplantation (MSCT international consortium).

The main contributions to REEM are:

  1. The impact of antineuronal antibodies and oligoclonal bands in MS and neuromyelitis optica in collaboration with X. Montalban, M. Villar, P. Villoslada, L. Ramió-Torrentà, J. Olascoaga/D Otaegui, R. Arroyo.
  2. The role of plasma exchange in acute CNS demyelination in collaboration with X. Montalban, L. Ramió-Torrentà; 3. the role of conventional and non-conventional MRI as prognostic factor in collaboration with P. Villoslada.
  3. Genomics studies in collaboration with X. Montalban, O. Fernández, G. Izquierdo, J. Olascoaga/D Otaegui, K. Vanderbroeck, R. Arroyo/E. Urcelay.
  • Publicaciones del grupo:

    PubMed